These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33832450)

  • 1. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
    Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
    BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
    Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
    Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
    Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
    Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
    Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
    J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan Amazon.
    Baumann A; Magris MM; Urbaez ML; Vivas-Martinez S; Durán R; Nieves T; Esen M; Mordmüller BG; Theisen M; Avilan L; Metzger WG
    Malar J; 2012 Feb; 11():46. PubMed ID: 22335967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
    Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
    Malar J; 2011 May; 10():108. PubMed ID: 21529376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV infection drives IgM and IgG3 subclass bias in Plasmodium falciparum-specific and total immunoglobulin concentration in Western Kenya.
    Odhiambo EO; Datta D; Guyah B; Ayodo G; Ondigo BN; Abong'o BO; John CC; Frosch AEP
    Malar J; 2019 Aug; 18(1):297. PubMed ID: 31470903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
    Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
    Nouatin O; Mengue JB; Dejon-Agobé JC; Fendel R; Ibáñez J; Ngoa UA; Edoa JR; Adégbité BR; Honkpéhédji YJ; Zinsou JF; Hounkpatin AB; Moutairou K; Homoet A; Esen M; Kreidenweiss A; Hoffman SL; Theisen M; Luty AJF; Lell B; Agnandji ST; Mombo-Ngoma G; Ramharter M; Kremsner P; Mordmüller B; Adegnika AA
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009361. PubMed ID: 34061838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
    Esen M; Kremsner PG; Schleucher R; Gässler M; Imoukhuede EB; Imbault N; Leroy O; Jepsen S; Knudsen BW; Schumm M; Knobloch J; Theisen M; Mordmüller B
    Vaccine; 2009 Nov; 27(49):6862-8. PubMed ID: 19755144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine profiles of
    Amoani B; Adu B; Frempong MT; Sarkodie-Addo T; Victor Nuvor S; Abu EK; Harrison LM; Cappello M; Gyan B; Wilson MD
    Cytokine X; 2019 Dec; 1(4):100014. PubMed ID: 33604551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
    Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
    PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
    Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
    Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium.
    Mutapi F; Roussilhon C; Mduluza T; Druilhe P
    Mem Inst Oswaldo Cruz; 2007 Jun; 102(3):405-9. PubMed ID: 17568947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.